ALNY Alnylam Pharmaceuticals, Inc.

-3.70  -5%
Previous Close 69.50
Open 69.27
Price To book 7.20
Market Cap 5.67B
Shares 86,190,000
Volume 1,356,852
Short Ratio 12.01
Av. Daily Volume 1,100,670

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial design agreed to by FDA - noted April 26, 2017.
Phase 1 additional data due June 2017 with a Phase 3 trial to be initiated in late 2017.
Acute hepatic porphyrias
Phase 1/2 trial initiated July 2016. Data are due mid 2017
Chronic hepatitis B virus (HBV)
Phase 1/2 initiated March 2016. Initial data released September 2016.
Primary Hyperoxaluria Type 1 (PH1)
Phase 3 data due mid-2017.
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3 trial discontinued October 2016.
ATTR in patients with familial amyloidotic cardiomyopathy (FAC)
Phase 1/2 initial data presented at ASH 2016.
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 3 program to be initiated 3Q 2017.
Fitusiran (ATLAS)
Development plan to be confirmed following APOLLO data release in mid 2017.
ATTR amyloidosis

Latest News

  1. Regeneron Presents Positive Phase II Data on HoFH Candidate
  2. Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline
  3. Biotech Movers: Inovio, Neurocrine, Alnylam
  4. Alnylam Pharmaceuticals Prices Public Offering of Common Stock
  5. Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock
  6. Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3%
  7. How Ionis Helped Rival Alnylam — But Tanked Itself — On A Key Trial
  8. Safety Concerns Ding Ionis
  9. Why Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today
  10. Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Financial Officer
  11. Edited Transcript of ALNY earnings conference call or presentation 5-May-17 12:30pm GMT
  12. ETFs with exposure to Alnylam Pharmaceuticals, Inc. : May 11, 2017
  13. Alnylam Pharmaceuticals, Inc. Earnings: All Eyes on APOLLO
  14. Alnylam to Webcast Presentations at Upcoming May Investor Conferences
  15. Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
  16. Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders
  17. Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y
  18. Alnylam reports 1Q loss
  19. Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity
  20. Investor Network: Alnylam Pharmaceuticals, Inc to Host Earnings Call